141 related articles for article (PubMed ID: 12241117)
1. Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab.
Pels H; Schulz H; Manzke O; Hom E; Thall A; Engert A
J Neurooncol; 2002 Sep; 59(3):213-6. PubMed ID: 12241117
[TBL] [Abstract][Full Text] [Related]
2. Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature.
Pels H; Schulz H; Schlegel U; Engert A
Onkologie; 2003 Aug; 26(4):351-4. PubMed ID: 12972702
[TBL] [Abstract][Full Text] [Related]
3. Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma.
Harjunpää A; Wiklund T; Collan J; Janes R; Rosenberg J; Lee D; Grillo-López A; Meri S
Leuk Lymphoma; 2001 Aug; 42(4):731-8. PubMed ID: 11697503
[TBL] [Abstract][Full Text] [Related]
4. Successful use of intraventricular and intravenous rituximab therapy for refractory primary CNS lymphoma in a child.
Akyuz C; Aydin GB; Cila A; Akalan N; Soylemezoglu F; Cengiz M; Yazici N; Buyukpamukcu M
Leuk Lymphoma; 2007 Jun; 48(6):1253-5. PubMed ID: 17577799
[No Abstract] [Full Text] [Related]
5. Intraventricular Rituximab in Pediatric CD20-positive Refractory Primary Central Nervous System Lymphoma.
Wada-Shimosato Y; Ikeda J; Tsujimoto SI; Sasaki K; Yanagimachi M; Kajiwara R; Shiba N; Murata H; Kawahara N; Yamanaka S; Tanoshima R; Ito S
J Pediatr Hematol Oncol; 2019 Oct; 41(7):571-573. PubMed ID: 30124546
[TBL] [Abstract][Full Text] [Related]
6. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
[TBL] [Abstract][Full Text] [Related]
7. Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma.
Heinzerling L; Dummer R; Kempf W; Schmid MH; Burg G
Arch Dermatol; 2000 Mar; 136(3):374-8. PubMed ID: 10724200
[TBL] [Abstract][Full Text] [Related]
8. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
Kerl K; Prins C; Saurat JH; French LE
Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389
[TBL] [Abstract][Full Text] [Related]
9. Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab.
Bonnekoh B; Schulz M; Franke I; Gollnick H
J Cancer Res Clin Oncol; 2002 Mar; 128(3):161-6. PubMed ID: 11935303
[TBL] [Abstract][Full Text] [Related]
10. [Measurement of rituximab concentration in the cerebrospinal fluid in CNS lymphoma].
Kikuchi A; Kawada H; Iwaki Y; Machida S; Tsuchiya T; Fukuda R; Hotta T
Rinsho Ketsueki; 2004 Dec; 45(12):1255-7. PubMed ID: 15678918
[TBL] [Abstract][Full Text] [Related]
11. Successful long-term control of lymphomatous meningitis with intraventricular rituximab.
Birnbaum T; Baumgarten Lv; Dudel C; Straube A
J Clin Neurosci; 2014 Feb; 21(2):356-8. PubMed ID: 24054402
[TBL] [Abstract][Full Text] [Related]
12. Using human CD20-transfected murine lymphomatous B cells to evaluate the efficacy of intravitreal and intracerebral rituximab injections in mice.
Mineo JF; Scheffer A; Karkoutly C; Nouvel L; Kerdraon O; Trauet J; Bordron A; Dessaint JP; Labalette M; Berthou C; Labalette P
Invest Ophthalmol Vis Sci; 2008 Nov; 49(11):4738-45. PubMed ID: 18552383
[TBL] [Abstract][Full Text] [Related]
13. Leukemic and meningeal relapse of CD5+ intravascular large B-cell lymphoma with down-modulation of CD20 after rituximab therapy.
Ohno T; Sakamoto T; Mizumoto C; Miyoshi T; Ueda M; Takeoka T; Yamashita K; Hishita T; Hada S
Int J Hematol; 2006 Jul; 84(1):74-8. PubMed ID: 16867907
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
15. Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma.
Kadoch C; Li J; Wong VS; Chen L; Cha S; Munster P; Lowell CA; Shuman MA; Rubenstein JL
Clin Cancer Res; 2014 Feb; 20(4):1029-41. PubMed ID: 24190981
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of intrathecal rituximab in children with B cell lymphoid CD20+ malignancies: An international retrospective study.
Ceppi F; Weitzman S; Woessmann W; Davies K; Lassaletta A; Reismüller B; Mellgren K; Uyttebroeck A; Maia I; Abdullah S; Miakova N; Glaser D; Cohn R; Abla O; Attarbaschi A; Alexander S
Am J Hematol; 2016 May; 91(5):486-91. PubMed ID: 26872652
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy.
Clarke LE; Bayerl MG; Ehmann WC; Helm KF
J Cutan Pathol; 2003 Aug; 30(7):459-62. PubMed ID: 12859745
[TBL] [Abstract][Full Text] [Related]
18. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
Enting RH; Demopoulos A; DeAngelis LM; Abrey LE
Neurology; 2004 Sep; 63(5):901-3. PubMed ID: 15365145
[TBL] [Abstract][Full Text] [Related]
19. Treatment of primary central nervous system lymphoma with induction of complement-dependent cytotoxicity by intraventricular administration of autologous-serum-supplemented rituximab.
Takami A; Hayashi T; Kita D; Nishimura R; Asakura H; Nakao S
Cancer Sci; 2006 Jan; 97(1):80-3. PubMed ID: 16367925
[TBL] [Abstract][Full Text] [Related]
20. Imaging of central nervous system lymphomas with iodine-123 labeled rituximab.
Dietlein M; Pels H; Schulz H; Staak O; Borchmann P; Schomäcker K; Fischer T; Eschner W; Pogge von Strandmann E; Schicha H; Engert A; Schnell R
Eur J Haematol; 2005 Apr; 74(4):348-52. PubMed ID: 15777348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
